Skip to main content

Foresite Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

129
Companies
$15.9B
Total invested
$127.8M
Avg. check
17
Industries
Biotechnology 21Health Care 16Therapeutics 11Biopharma 9Life Science 8Medical 7+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 129
Venatorx Pharmaceuticals
September 2022

Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.

Health Care · Malvern$24.7M Venture - Series Unknown
Mindstrong Health
September 2022

Mindstrong is a virtual mental health platform.

Health Care · Menlo Park$250K Grant
Korsana Biosciences
September 2025

Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.

Biopharma · Waltham$150.0M Series A
XinThera
August 2021

XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.

Biotechnology · San Diego$50.0M Series B
Kriya Therapeutics
August 2025

Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.

Biotechnology · Palo Alto$320.8M Series D
Quantum SI
July 2025

Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.

Biotechnology · Guilford$50.0M Post-IPO Equity
ALX Oncology
June 2026

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Biopharma · San Francisco$10.0M Post-IPO Debt
Pharvaris
May 2026

Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.

Biotechnology · Zug$132.3M Post-IPO Equity
Tempest Therapeutics
May 2026

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.

Biotechnology · San Francisco$2.0M Post-IPO Equity
ORIC Pharmaceuticals
May 2025

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Biopharma · South San Francisco$125.0M Post-IPO Equity
Relay Therapeutics
May 2026

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Biotechnology · Cambridge$275.0M Post-IPO Equity
Cerevance
May 2026

Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.

Biotechnology · Boston$20.0M Series C
Intellia Therapeutics
April 2026

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

Biotechnology · Cambridge$180.0M Post-IPO Equity
GH Research
April 2026

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$117.5M Post-IPO Equity
Juvenescence
April 2025

Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.

Biopharma · Dublin$76.0M Series B
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post-IPO Equity
ImageneBio
April 2026

ImageneBio is dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases

Biopharma · San Diego$30.0M Post-IPO Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post-IPO Equity
Orchard Therapeutics
March 2023

Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.

Biotechnology · London$34.0M Post-IPO Equity
Seaport Therapeutics
March 2026

Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.

Biopharma · Boston$15.0M Grant
Pinnacle Medicines
March 2026

Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs.

Biopharma · Doylestown$89.0M Series B
Generation Bio
March 2023

Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.

Biotechnology · Cambridge$76.0M Post-IPO Equity
LifeMine Therapeutics
March 2022

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.

Biotechnology · Cambridge$175.0M Series C
Engrail Therapeutics
March 2024

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

Health Care · San Diego$167.0M Series B

Where Foresite Capital invests

Biotechnology21
Health Care16
Therapeutics11
Biopharma9
Life Science8
Medical7

About Foresite Capital's portfolio

How many companies has Foresite Capital invested in?

Foresite Capital has invested in 129 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Foresite Capital invest in?

Foresite Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Life Science. The firm invests across 17 different industry categories.

What is Foresite Capital's largest investment?

Among tracked funding rounds, Kriya Therapeutics received $320.8M in a Series D round. Foresite Capital's total known invested capital is $15.9B.

What is the average investment size for Foresite Capital?

Foresite Capital's average investment size is $127.8M across its portfolio of 129 companies.

What are Foresite Capital's most recent investments?

Recent Foresite Capital portfolio additions include Venatorx Pharmaceuticals, Mindstrong Health, Korsana Biosciences, XinThera, Kriya Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 129 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →